A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerative Colitis.
The ODYSSEY study aims to evaluate the safety and tolerability of OD-07656 in participants with moderately to severely active UC.
If eligible for the study, your participation is expected to be up to 56 weeks (including the Screening Period).
Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?
